Patients with localized high-risk prostate cancer and midline radiotracer activity in the prostate had over double the incidence of urethral hyperintensity on T2W MRI, according to research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Post-void magnetic resonance imaging (MRI) may provide enhanced clarity as to the nature of midline prostate-specific membrane antigen (PSMA) radiotracer uptake on positron emission tomography (PET) scans for patients with localized, high-risk prostate cancer.
In a study presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, researchers reviewed PSMA PET and T2W MRI imaging for 84 patients with localized, high-risk prostate cancer. Sixty-eight patients had no midline prostate activity on PSMA PET and 16 patients who had had midline radiotracer activity with 18F-DCFPyL, according to the study.
The study authors found that 75 percent of patients with prostate midline tracer uptake on PSMA PET had urethral hyperintensity on post-void MRI exams in comparison to 31 percent of patients with no midline tracer activity on PSMA PET imaging.
For patients with urethral hyperintensity on post-void MRI exams, researchers noted significantly increased mean axial (7.25 mm vs. 2.81 mm) and sagittal (12.25 mm vs. 5.43 mm) prostatic urethral measurements in comparison to MRI findings for those with no prostate midline tracer uptake on PSMA PET imaging.
Here one can see PSMA PET/CT imaging that suggests a possible midline lesion and a subsequent MRI finding of urine stagnation. (Images courtesy of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.)
“Our findings suggest that PSMA uptake within the midline of the prostate is more commonly observed in patients with a prominently visible prostatic urethra at MRI, a finding that is likely associated with the stagnation of urine containing PSMA tracer,” wrote lead study author David G. Gelikman, an MRSP research scholar at the National Institutes of Health in Bethesda, Md., and colleagues.
The researchers emphasized that clinicians may misread PSMA activity within the prostatic urethra as intraprostatic lesions. Accordingly, they recommended subsequent assessment with MRI.
“PSMA uptake in the prostatic midline is often linked with urine stagnation in the prostatic urethra and can lead to misinterpretation on PSMA PET/CT,” noted Gelikman and colleagues. “Using post-void MRIs may help reduce false positives.”
Reference
1. Gelikman DG, Gonzalez EM, Lindenberg L, et al. Effect of urinary stagnation in the prostatic urethra on generating false-positive midline lesions on 18F-DCFPyL PSMA PET/CT. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU, San Francisco, Calif. Poster available at https://conferences.asco.org/gu/abstracts . Accessed January 26, 2024.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.